RTP Mobile Logo
Real-Life Decisions: Clinical Investigators Provide Their Perspectives on Actual Patients with Metastatic Colorectal, Gastric and Pancreatic Cancer
Released June 2016

Faculty presentations from a CME symposium held at the 2016 Gastrointestinal Cancers Symposium. Featuring perspectives from Drs Tanios Bekaii-Saab, Charles S Fuchs, Axel Grothey, Eunice L Kwak, Heinz-Josef Lenz and Alberto F Sobrero. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of gastrointestinal (GI) cancers.

    OVERVIEW OF ACTIVITY
    Given the prevalent nature of the disease, extensive resources are allocated to colorectal cancer (CRC) research and education. Interestingly, however, although individually less frequently encountered, the collection of other “non-CRC” GI cancers account for more per annum cancer-related deaths than those attributed to tumors of the colon and rectum combined. Importantly, among this collection of distinct tumors, two areas in particular — gastric and pancreatic cancer — have witnessed several recent advances that have already drastically altered or have the potential to affect current treatment considerations and approaches.

    These video highlights from a CME symposium held during the 2016 Gastrointestinal Cancers Symposium feature presentations given by leading investigators in the management of GI cancers. By providing information on important new developments, this activity will address the most pressing educational needs of practitioners involved in the multidisciplinary management of colorectal, gastric and pancreatic cancer.

    LEARNING OBJECTIVES

    • Appraise recent data on therapeutic advances and changing practice standards in colorectal, gastric and pancreatic cancer, and integrate this information, as appropriate, into current clinical care.
    • Develop a long-term care plan for individuals diagnosed with metastatic CRC, considering the patient’s biomarker profile, exposure to prior systemic therapy, symptomatology, performance status and personal goals for treatment.
    • Communicate with patients and their caregivers regarding the incidence and manifestation of side effects and toxicities associated with systemic agents and regimens commonly used in the management of advanced GI cancers.
    • Individualize local and systemic treatment for patients with liver-only or liver-dominant metastatic CRC.
    • Use HER2 status, clinical factors and patient perspectives to optimize the selection and sequence of systemic therapy for patients with locally advanced or metastatic gastric or gastroesophageal cancer.
    • Consider age, performance status and other clinical and logistical factors in the selection of systemic therapy for patients with locally advanced or metastatic pancreatic cancer.
    • Appraise the rationale for and clinical data with investigational anti-PD-1 and/or anti-PD-L1 antibodies in the treatment of GI cancers.
    • Describe the proposed mechanisms of action of and recall new data with investigational agents demonstrating promising activity in colorectal, gastric and pancreatic cancer, and use this information to counsel appropriate patients regarding ongoing trials.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of this CME activity enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    This CME activity consists of a video component. To receive credit, the participant should watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/GICancers16/CME.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Tanios Bekaii-Saab, MD
    Section Chief, Gastrointestinal Oncology
    Chair, OSUCCC Gastrointestinal Disease Research Group
    Professor of Medicine and Pharmacy
    The Ohio State University – James Cancer Hospital
    Columbus, Ohio

    Consulting Agreements: Amgen Inc, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, EMD Serono Inc, Genentech BioOncology, Lilly, Merrimack Pharmaceuticals Inc, Pfizer Inc, Taiho Oncology Inc; Data and Safety Monitoring Board: Exelixis Inc.

    Charles S Fuchs, MD, MPH
    Director, Center for Gastrointestinal Cancer
    Dana-Farber/Harvard Cancer Center
    Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Consulting Agreements: Amgen Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Lilly, Merck, Pfizer Inc, Sanofi, Takeda Oncology.

    Axel Grothey, MD
    Professor of Oncology
    Department of Medical Oncology
    Mayo Clinic
    Rochester, Minnesota

    Advisory Committee: Amgen Inc, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Celgene Corporation, Genentech BioOncology, Lilly; Contracted Research: Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Eisai Inc, Genentech BioOncology, Lilly, Merck, Sanofi.

    Eunice L Kwak, MD, PhD
    Assistant in Medicine
    Massachusetts General Hospital
    Assistant Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    No relevant conflicts of interest to disclose.

    Heinz-Josef Lenz, MD
    Professor of Medicine and Preventive Medicine
    J Terrence Lanni Chair for Cancer Research
    Director, GI Oncology Program
    Co-Director, Clinical Research
    Scientific Director, Cancer Genetics Unit
    USC/Norris Comprehensive Cancer Center
    Los Angeles, California

    Advisory Committee and Consulting Agreements: Bayer HealthCare Pharmaceuticals, EMD Serono Inc, Genentech BioOncology, Merck, Roche Laboratories Inc; Contracted Research: Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, EMD Serono Inc, Genentech BioOncology, Merck, Roche Laboratories Inc; Other Remunerated Activities: Takeda Oncology.

    Alberto F Sobrero, MD
    Head of the Medical Oncology Unit
    Ospedale San Martino
    Genoa, Italy

    Consulting Agreements: Amgen Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Lilly, Merck; Speakers Bureau: Amgen Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Lilly, Merck, Roche Laboratories Inc, Sanofi, Takeda Oncology.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Boston Biomedical Pharma Inc, Genentech BioOncology, Incyte Corporation, Lilly, Merrimack Pharmaceuticals Inc, Sirtex Medical Ltd and Taiho Oncology Inc.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: June 2016
    Expiration date: June 2017

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

View video: